Causal effect of interleukin (IL)-6 on blood pressure and hypertension: A mendelian randomization study
- 1 March 2024
- journal article
- research article
- Published by Springer Nature in Immunogenetics
- Vol. 76 (2) , 123-135
Abstract
To examine whether circulating interleukin-6 (IL-6) levels (CirIL6) have a causal effect on blood pressure using Mendelian randomization (MR) methods. We used data from genome-wide association studies (GWAS) of European ancestry to obtain genetic instruments for circulating IL-6 levels and blood pressure measurements. We applied several robust MR methods to estimate the causal effects and to test for heterogeneity and pleiotropy. We found that circulating IL-6 had a significant positive causal effect on systolic blood pressure (SBP) and pulmonary arterial hypertension (PAH), but not on diastolic blood pressure (DBP) or hypertension. We found that as CirIL6 genetically increased, SBP increased using Inverse Variance Weighted (IVW) method (for ukb-b-20175, β = 0.082 with SE = 0.032, P = 0.011; for ukb-a-360, β = 0.075 with SE = 0.031, P = 0.014) and weighted median (WM) method (for ukb-b-20175, β = 0.061 with SE = 0.022, P = 0.006; for ukb-a-360, β = 0.065 with SE = 0.027, P = 0.014). Moreover, CirIL6 may be associated with an increased risk of PAH using WM method (odds ratio (OR) = 15.503, 95% CI, 1.025–234.525, P = 0.048), but not with IVW method. Our study provides novel evidence that circulating IL-6 has a causal role in the development of SBP and PAH, but not DBP or hypertension. These findings suggest that IL-6 may be a potential therapeutic target for preventing or treating cardiovascular diseases and metabolic disorders. However, more studies are needed to confirm the causal effects of IL-6 on blood pressure and to elucidate the underlying mechanisms and pathways.Keywords
Funding Information
- Natural Science Foundation of China (81102200)
This publication has 100 references indexed in Scilit:
- Regulation of alveolar macrophage death in pulmonary fibrosis: a reviewApoptosis, 2023
- Effects of blood pressure and antihypertensive drugs on osteoarthritis: a mendelian randomized studyAging Clinical and Experimental Research, 2023
- A Guide for Understanding and Designing Mendelian Randomization Studies in the Musculoskeletal FieldJBMR Plus, 2022
- Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic TargetCurrent Hypertension Reports, 2021
- Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseasesJournal of Cellular Physiology, 2021
- Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive SymptomsJAMA Psychiatry, 2021
- Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart FailureCardiovascular Drugs and Therapy, 2020
- A comparison of robust Mendelian randomization methods using summary dataGenetic Epidemiology, 2020
- Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median EstimatorGenetic Epidemiology, 2016
- The pro- and anti-inflammatory properties of the cytokine interleukin-6Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011